查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835263

肝炎檢測解決方案/診斷市場（按技術、產品類型、最終用戶、檢測類型和應用）—全球預測 2025-2032

Hepatitis Test Solution/Diagnosis Market by Technology, Product Type, End User, Test Type, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肝炎檢測解決方案/診斷市場將成長至 57.9 億美元，複合年成長率為 5.71%。

主要市場統計數據
基準年2024年 37.1億美元
預計2025年 39.2億美元
預測年份：2032年 57.9億美元
複合年成長率（%） 5.71%

肝炎診斷領域的簡明策略框架，重點在於臨床需求促進因素、技術融合以及決策者的營運要求

肝炎診斷是公共衛生緊迫性和快速技術進步的交匯點。層析法、免疫測量平台和分子診斷技術的最新發展正在擴展照護現場和實驗室檢測能力，而不斷變化的監管預期和付款人監督正在再形成診斷供應商和醫療保健提供者的優先事項。在這種動態環境中，相關人員必須協調臨床需求與營運現實（從試劑採購到儀器通量），以確保為不同患者群體提供及時且準確的診斷。

本引言概述了定義肝炎檢測和診斷現狀的關鍵因素。它概述了為何對診斷創新進行策略性投資至關重要，最終用戶行為的轉變將如何影響採購和部署，以及產業領導者在調整研發、商業和供應鏈策略時應關注的重點。在此基準上，以下章節將探討轉型變革、關稅阻力、細分市場考量、區域動態、競爭壓力以及指南短期和中期決策的實用建議。

技術融合、醫療分散化和不斷變化的監管預期如何重塑肝炎診斷策略和交付模式

由於技術進步、數位整合以及醫療服務模式的轉變，肝炎檢測領域正在發生重大變化。層析法技術正變得越來越自動化和靈敏，免疫測量平台也朝著更高的通量和更快的周轉速度發展，從而支持更廣泛的篩檢舉措。同時，分子診斷正受益於檢測化學和熱控制的創新，從而實現了穩健的PCR和恆溫擴增工作流程，縮短了獲得結果的時間，並拓寬了檢測管道。這些技術進步與軟體、連接性和實驗室自動化的進步相輔相成，提升了資料管理和結果報告的效率。

同時，業界重點正轉向分散檢測，並將診斷整合到傳統醫院實驗室以外的護理路徑中。即時檢測和近患者檢測正日益普及，而居家醫療場景則需要重新思考使用者介面和樣本處理。法律規範也在根據這些交付模式不斷發展，更加重視在不同環境下檢驗的性能以及與電子醫療系統的互通性。總而言之，這些變化代表著結構性重組。市場正在從孤立的、以實驗室為中心的模式轉向更加網路化、以患者為中心的診斷生態系統，這不僅需要技術靈活性，還需要製造商、支付方和醫療保健提供者之間建立策略夥伴關係。

定性分析近期政策週期中關稅政策的發展如何放大供應鏈波動、重塑籌資策略並影響銷售計劃。

美國將在2025年之前加徵關稅，這將對整個肝炎診斷供應鏈和商業化策略產生一系列複雜的營運和策略影響。對於依賴跨境採購儀器、耗材和試劑的製造商而言，關稅加劇了供應鏈彈性、庫存管理和貨物總到岸成本的討論。因此，企業正在重新評估其採購佈局，多元化供應商基礎，並優先選擇能夠為關鍵零件提供安全、合規且成本穩定的管道的合作夥伴。

除了採購之外，關稅也改變了產品發布計畫和市場進入經濟。一些公司正在加速製造和組裝的在地化，以減輕關稅的影響，而其他公司則在重新設計產品包裝和零件選擇，以減輕關稅分類的影響。這些適應性反應也影響著供應商關係，長期合約和策略聯盟正在成為穩定投入成本的途徑。從供應方的觀點來看，採購團隊越來越注重長期服務協議和捆綁產品，以保護企業預算免受關稅引發的波動影響。總而言之，到2025年，關稅政策的累積影響強化了策略供應鏈設計、合規在地化和商業性可行的風險緩解策略的重要性。

將診斷技術、產品類型、最終用戶需求、測試方式和應用與策略創新和商業性協調聯繫起來的深入細分分析

透過對關鍵細分市場的細緻分析，可以清楚地了解診斷創新和商業性重點的交會點。相關技術包括層析法方法，例如流動注射分析和高效液相層析；免疫檢測，例如化學冷光免疫檢測、ELISA 和快速免疫檢測；以及分子診斷，例如等溫擴增、PCR 和即時PCRPCR。這些技術選擇會影響產品設計及其最支援的臨床工作流程，從集中式確認檢測到分散式篩檢篩檢。

從產品類型來看，儀器可分為適用於小型實驗室的桌上型機型和用於集中式設施的高通量機型。套件和試劑分為層析法套件、免疫檢測套件和分子測定試劑套件，每種試劑盒需要不同的供應鏈和品質保證流程。軟體和服務可實現結果解釋、連接和耗材生命週期管理，並日益成為硬體的補充。從最終用戶的觀點，血庫、診所、診斷實驗室（包括醫院內和獨立實驗室）、居家醫療機構和醫院（包括綜合和專科中心）各自都有自己獨特的採購模式、預期通量和報銷限制。測試類型分為篩檢和確認測試，確認測試方法包括基於 ELISA 的確認測試和基於 PCR 的確認測試，以支援臨床決策。最後，應用分為臨床診斷和研究，臨床環境優先考慮經過驗證的、符合法規的工作流程，而研究環境則強調靈活性和新穎的檢測方法開發。這些細分為針對創新、商業性推廣和商業投資提供了一個多維框架。

比較區​​域動態，說明基礎設施、監管和投資重點如何形成肝炎檢測採用和擴大規模的差異化策略

肝炎診斷的區域動態受醫療保健基礎設施、管理體制和投資重點差異的影響。在美洲，先進的實驗室網路、分子平台的廣泛採用以及檢測服務供應商的整合，為高通量自動化和整合數據解決方案創造了有利環境。同時，服務不足的人口和農村醫療保健環境正在推動快速免疫檢測和即時診斷 (POC) 解決方案的應用，以改善篩檢和醫療聯繫。

在歐洲部分地區，成熟的法律規範和報銷系統支援先進實驗室和確認性檢測的部署，而中東和非洲的許多市場則專注於可擴展、經濟高效的篩檢解決方案和能力建設。官民合作關係和捐助方資助的計畫通常在擴大檢測管道方面發揮關鍵作用。在亞太地區，快速的現代化、國內製造業的成長以及對分子檢測能力的大力投資正在加速PCR和即時PCR平台的普及，但由於市場成熟度不同，供應商需要根據當地情況客製化其分銷、服務模式和定價策略。這些地區差異凸顯了每個地區都需要適應性的商業性方法和細緻的產品系列。

肝炎診斷領域的競爭態勢以創新主導的差異化、策略聯盟和選擇性整合為特徵。大型診斷公司正在投資平台擴充性、檢測組合廣度以及軟體支援服務，以確保長期的客戶關係。儀器製造商和試劑套件開發商之間的合作日益普遍，從而促成​​了整合解決方案，簡化了採購流程，降低了最終用戶的進入門檻。同時，規模較小的專業化公司正在推動檢測靈敏度、即時診斷可用性和試劑穩定性等細分領域的進步，並且往往成為尋求快速產能擴張的大型公司的收購目標。

除了產品創新之外，商業策略還強調服務可靠性、監管支援和靈活的資金籌措模式。能夠提供可靠檢驗數據、可擴展生產能力和上市後支援的公司在與醫院和大型實驗室網路的採購談判中擁有優勢。與區域經銷商和臨床網路建立策略聯盟，進一步拓展了其在碎片化市場的影響力。此外，隨著供應商優先考慮正常運作時間和可預測的營運成本，對用於結果管理、遠端設備監控和耗材預測的數位化工具的投資正成為其競爭優勢。這些因素共同作用，正在建立一個生態系統，該生態系統要求以卓越技術為基礎的商業性執行時間和服務交付。

診斷公司可採取的可行策略步驟，以建立供應鏈彈性、擴展部署模型，並使商業性價值與醫療保健系統優先事項保持一致

診斷產業的領導者應採取一系列切實可行的措施，在應對短期挑戰的同時，著眼於長期成長。首先，優先考慮供應鏈多元化，並考慮關鍵製造和組裝的策略性區域化，以降低關稅波動和運輸中斷帶來的風險。其次，透過模組化平台和開發強大的連接和解讀藍圖，使產品路線圖與集中式確認檢測和分散式篩檢的雙重需求相協調，以支援多樣化的用例。

第三，深化與醫院、診斷實驗室和社區診所等終端使用者的夥伴關係，共同開發解決運作、耗材物流和訓練問題的服務模式。第四，投資於檢測的穩健性和簡化的工作流程，使其能夠在居家醫療和資源匱乏的環境中應用，同時透過嚴格的驗證確保合規性。最後，透過以結果為導向的合約和捆綁服務協議來強化商業性提案，以減少採購摩擦，並向付款人和醫療保健提供者展示清晰的價值。共同採取這些措施將增強韌性，加速跨環境的採用，並使商業性回報與公共衛生影響保持一致。

對證據來源、專家諮詢和分析方法的透明描述，為相關人員提供可操作的見解

本研究旨在整合多種證據流，提供均衡的、以實踐者為中心的見解。一級資訊來源包括同行評審的科學文獻、監管指導文件、儀器和檢測性能報告以及公共領域的臨床實踐指南，這些構成了評估技術能力和臨床效用的基礎。二級資訊來源包括行業公告、公開的財務資訊以及對實驗室主任、採購人員和監管專家的專家訪談，以揭示商業性和營運動態。

我們的分析方法將定性趨勢分析與基於情境的風險評估相結合，以評估供應鏈敏感度、關稅風險和商業化路徑。我們應用細分框架，將技術選擇與最終用戶需求和區域限制進行映射。在某些情況下，我們透過對多個獨立資訊來源進行三角測量進行交叉檢驗，以確保我們主要發現的穩健性。在整個調查方法中，我們優先考慮假設的透明度以及證據與解釋之間的清晰聯繫，以便決策者能夠根據自身的業務和監管環境調整我們的結論。

結論強調，需要製定整合策略。

總而言之，肝炎診斷正處於曲折點，技術的日益成熟、交付模式的不斷演變以及政策的轉變，既帶來了機遇，也帶來了複雜性。層析法、免疫測量和分子診斷法的進步正在擴展臨床醫生和公共衛生相關人員可用的套件，而護理途徑的轉變則需要能夠適應中心實驗室、診所和居家照護環境的解決方案。關稅趨勢和區域差異增加了策略複雜性，需要細緻的供應鏈和商業規劃。

對於該領域的領導者而言，成功的關鍵在於將卓越的技術、靈活的營運和以客戶為中心的服務模式相結合。那些投資於平台靈活性、區域製造策略以及與最終用戶的深度夥伴關係的公司，將最有能力將診斷創新轉化為檢測、護理銜接和患者預後的可衡量改進。這項證據凸顯了製定協調一致的策略的必要性，該策略將連接研發、監管和商業領域，以充分發揮肝炎檢測技術進步的潛力。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 雲端基礎患者資料管理平台與肝炎診斷照護現場NAT檢測設備的整合
  • 引入多重快速診斷測試面板，可在資源有限的環境中同時檢測B型肝炎、C型肝炎和戊型肝炎抗原
  • 利用智慧型手機讀取功能開發用於定量監測B型肝炎表面抗原水平的數位免疫檢測平台
  • 擴大 CRISPR 為基礎的分子診斷技術在C型肝炎病毒RNA 超靈敏檢測的應用
  • 增加對微流體實驗室晶片設備的投資，用於農村診所的攜帶式、低成本肝炎血清學檢測
  • 擴大針對服務不足人口的肝炎篩檢舉措，整合家庭自採集試劑套件和遠端醫療

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 肝炎檢測解決方案/診斷市場（按技術）

  • 層析法
    • FIA
    • HPLC
  • 免疫檢測
    • 化學冷光免疫檢測
    • 伊麗莎
    • 快速免疫檢測
  • 分子診斷
    • 等溫擴增
    • PCR
    • 即時PCR

9. 肝炎檢測解決方案/診斷市場（依產品類型）

  • 裝置
    • 桌上型裝置
    • 高通量儀器
  • 套件和試劑
    • 層析法套件
    • 免疫檢測套件
    • 分子檢測試劑套件
  • 軟體和服務

第 10 章。 肝炎檢測解決方案/診斷市場（按最終用戶）

  • 血庫
  • 診所
  • 診斷實驗室
    • 醫院附設檢查室
    • 獨立研究機構
  • 家庭環境
  • 醫院
    • 綜合醫院
    • 專科醫院

第 11 章 肝炎檢測解決方案/診斷市場（依檢測類型）

  • 確認檢查
    • ELISA 確認試驗
    • PCR確認試驗
  • 篩檢測試

第12章肝炎檢測解決方案/診斷市場（按應用）

  • 臨床診斷
  • 研究

13. 肝炎檢測解決方案/診斷市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章肝炎檢測解決方案/診斷市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 肝炎檢測解決方案/診斷市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • AbbVie Inc.
    • Avantor Inc.
    • Beckman Coulter, Inc.
    • Bio-Rad Laboratories Inc.
    • bioMerieux SA
    • Cepheid
    • Creative Diagnostics
    • DiaSorin SpA
    • Epitope Diagnostics, Inc.
    • Everlywell, Inc.
    • F. Hoffmann-La Roche AG
    • FUJIREBIO Inc.
    • GenMark Diagnostics, Inc.
    • Grifols SA
    • Hologic, Inc.
    • Laboratory Corporation of America Holdings
    • MedMira Inc.
    • Merck & Co., Inc
    • Meridian Bioscience, Inc.
Product Code: MRR-43127F727883

The Hepatitis Test Solution/Diagnosis Market is projected to grow by USD 5.79 billion at a CAGR of 5.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.71 billion
Estimated Year [2025] USD 3.92 billion
Forecast Year [2032] USD 5.79 billion
CAGR (%) 5.71%

Concise strategic framing of the hepatitis diagnostics environment highlighting clinical demand drivers, technological convergence, and operational imperatives for decision makers

The hepatitis diagnostics landscape sits at the nexus of public health urgency and rapid technological progress. Over recent years, developments in chromatography, immunoassay platforms, and molecular diagnostics have expanded testing capabilities across point-of-care and laboratory settings, while evolving regulatory expectations and payer scrutiny have reshaped priorities for diagnostic suppliers and healthcare providers. In this dynamic environment, stakeholders must reconcile clinical need with operational realities, from reagent sourcing to instrument throughput, to ensure timely and accurate diagnosis for diverse patient populations.

This introduction outlines the primary vectors that define the current state of hepatitis testing and diagnosis. It frames why strategic investment in diagnostic innovation is vital, how shifts in end-user behavior influence procurement and deployment, and what industry leaders should monitor as they align R&D, commercial, and supply chain strategies. By establishing this baseline, subsequent sections will examine transformational shifts, tariff-driven headwinds, segment-specific insights, regional dynamics, competitive imperatives, and pragmatic recommendations to guide near-term and medium-term decision-making.

How technological convergence, decentralization of care, and evolving regulatory expectations are reshaping hepatitis diagnostic strategies and delivery models

The landscape for hepatitis testing is undergoing transformative shifts driven by converging technology improvements, digital integration, and changing care delivery models. Chromatography techniques have become more automated and sensitive, while immunoassay platforms are moving toward higher throughput and faster turnaround, supporting expanded screening initiatives. Simultaneously, molecular diagnostics are benefitting from innovations in assay chemistry and thermal control, enabling robust PCR and isothermal amplification workflows that reduce time to result and broaden testing access. These technological advances are complemented by advances in software, connectivity, and laboratory automation that unlock new efficiencies in data management and result reporting.

Concurrently, industry priorities are shifting toward decentralization of testing and the integration of diagnostics into care pathways beyond traditional hospital laboratories. Point-of-care and near-patient testing adoption is rising, and home care scenarios are prompting rethinking of user interfaces and sample handling. Regulatory frameworks are evolving in response to these delivery models, placing greater emphasis on validated performance in diverse settings and interoperability with electronic health systems. Taken together, these changes represent a structural realignment: the market is moving from siloed laboratory-centric models to more networked, patient-centric diagnostic ecosystems that demand both technological flexibility and strategic partnerships between manufacturers, payers, and providers.

Qualitative analysis of how tariff policy developments have amplified supply chain volatility, reshaped sourcing strategies, and influenced commercialization planning through recent policy cycles

The imposition and escalation of tariffs in the United States through 2025 has created a complex set of operational and strategic effects across hepatitis diagnostic supply chains and commercialization strategies. For manufacturers reliant on cross-border sourcing of instruments, consumables, and reagents, tariff measures have intensified discussions about supply chain resilience, inventory management, and the total landed cost of goods. As a result, firms are reassessing sourcing footprints, diversifying supplier bases, and prioritizing partners that can offer secure, compliant, and cost-stable channels for critical components.

Beyond procurement, tariffs have altered product launch planning and go-to-market economics. Some organizations are accelerating the localization of manufacturing or assembly to mitigate exposure, while others are redesigning product packaging and component selection to reduce tariff classifications. These adaptive responses are also influencing supplier relationships, with long-term agreements and strategic alliances emerging as ways to stabilize input costs. From the provider perspective, procurement teams are increasingly focused on long-term service agreements and bundled offerings that insulate operational budgets from incremental duty-driven variability. Taken together, the cumulative impact of tariff policy through 2025 has heightened the premium on strategic supply chain design, regulatory-compliant localization, and commercially viable risk mitigation strategies.

In-depth segmentation analysis linking diagnostic technologies, product types, end-user requirements, test modalities, and applications to strategic innovation and commercial alignment

A granular view across primary segmentation axes clarifies where diagnostic innovation and commercial focus are converging. Based on technology, diagnostics activity spans chromatography methods that include flow injection analysis and high-performance liquid chromatography, immunoassay approaches such as chemiluminescent immunoassays, ELISA, and rapid immunoassays, and molecular diagnostics encompassing isothermal amplification, PCR, and real-time PCR, each offering distinct trade-offs in sensitivity, throughput, and deployment setting. These technological choices influence product design and the clinical workflows they best support, from centralized confirmatory testing to decentralized screening initiatives.

When viewed through product-type lenses, instruments differentiate between bench-top devices suited to smaller laboratories and high-throughput platforms for centralized facilities, while kits and reagents are segmented into chromatography kits, immunoassay kits, and molecular assay kits that require distinct supply chain and quality assurance processes. Software and services increasingly complement hardware offerings, enabling result interpretation, connectivity, and consumable lifecycle management. From an end-user perspective, blood banks, clinics, diagnostic laboratories-both hospital-based and independent-home care settings, and hospitals including general and specialized centers each present unique procurement models, throughput expectations, and reimbursement constraints. Test types divide into screening tests and confirmatory tests, where confirmatory modalities include ELISA-based confirmation and PCR-based confirmation methodologies that underpin clinical decision-making. Finally, applications split between clinical diagnostics and research, with clinical settings prioritizing validated, regulatory-compliant workflows and research environments focusing on flexibility and novel assay development. Together, these segmentations provide a multidimensional framework for targeting innovation, commercial outreach, and operational investments.

Comparative regional dynamics showing how infrastructure, regulation, and investment priorities shape differentiated strategies for hepatitis testing adoption and scale-up

Regional dynamics in hepatitis diagnostics are shaped by differences in healthcare infrastructure, regulatory regimes, and investment priorities. In the Americas, advanced laboratory networks, broad adoption of molecular platforms, and consolidated laboratory service providers create an environment that favors high-throughput automation and integrated data solutions. At the same time, pockets of underserved populations and rural care settings drive adoption of rapid immunoassays and point-of-care solutions to improve screening and linkage to care.

Across Europe, the Middle East, and Africa, heterogeneity is the dominant theme: established regulatory frameworks and reimbursement systems in parts of Europe support sophisticated laboratory deployments and confirmatory testing, while in many Middle Eastern and African markets the emphasis is on scalable, cost-effective screening solutions and capacity building. Public-private partnerships and donor-funded programs often play significant roles in expanding testing access. In the Asia-Pacific region, rapid modernization, domestic manufacturing growth, and strong investment in molecular testing capabilities are accelerating uptake of PCR and real-time PCR platforms, yet diverse market maturity levels mean suppliers must tailor distribution, service models, and pricing strategies to local contexts. These regional contrasts highlight the necessity of adaptive commercial approaches and regionally nuanced product portfolios.

Competitive dynamics in the hepatitis diagnostics space are characterized by innovation-led differentiation, strategic partnerships, and selective consolidation. Leading diagnostic firms are investing in platform extensibility, assay portfolio breadth, and software-enabled services to secure long-term customer relationships. Collaboration between instrument manufacturers and kit developers is increasingly common, enabling integrated solutions that simplify procurement and lower adoption barriers for end users. In parallel, smaller specialist companies are driving niche advances in assay sensitivity, point-of-care usability, and reagent stability, often becoming acquisition targets for larger players seeking rapid capability expansion.

Beyond product innovation, commercial strategies emphasize service reliability, regulatory support, and flexible financing models. Companies that can demonstrate robust validation data, scalable manufacturing capacity, and post-market support distinguish themselves in procurement conversations with hospitals and large laboratory networks. Strategic alliances with regional distributors and clinical networks further extend reach into fragmented markets. Moreover, investment in digital tools for result management, remote instrument monitoring, and consumable forecasting is becoming a competitive differentiator, as providers prioritize uptime and predictable operational costs. Collectively, these forces are shaping an ecosystem where technical excellence must be matched by proven commercial execution and service delivery.

Actionable strategic measures for diagnostics companies to build supply chain resilience, expand deployment models, and align commercial value with health system priorities

Industry leaders should pursue a set of pragmatic actions to navigate near-term headwinds while positioning for long-term growth. First, prioritize diversification of supply chains and consider strategic regionalization of critical manufacturing and assembly to reduce exposure to tariff volatility and transportation disruptions. Second, align product roadmaps to the dual needs of centralized confirmatory testing and decentralized screening by modularizing platforms and developing robust connectivity and interpretive software that supports diverse use cases.

Third, deepen partnerships with end users across hospitals, diagnostic laboratories, and community clinics to co-develop service models that address uptime, consumable logistics, and training. Fourth, invest in assay robustness and simplified workflows that enable use in home care and low-resource settings while ensuring regulatory compliance through rigorous validation. Finally, enhance commercial propositions with outcome-oriented contracting and bundled service agreements that reduce procurement friction and demonstrate clear value to payers and providers. Executed together, these steps will build resilience, accelerate adoption across varied settings, and align commercial returns with public health impact.

Transparent explanation of the evidence sources, expert consultations, and analytic approaches used to derive actionable insights for hepatitis diagnostic stakeholders

This research synthesis integrates multiple evidence streams to produce balanced, practitioner-focused insights. Primary sources include peer-reviewed scientific literature, regulatory guidance documents, device and assay performance reports, and public-domain clinical practice guidelines, which together ground assessments of technology capabilities and clinical utility. Secondary inputs draw on industry announcements, financial disclosures where publicly available, and subject-matter expert interviews with laboratory directors, procurement leads, and regulatory specialists to contextualize commercial and operational dynamics.

Analytical methods combine qualitative trend analysis with scenario-driven risk assessment to evaluate supply chain sensitivity, tariff exposure, and commercialization pathways. Segmentation frameworks were applied to map technology choices to end-user requirements and regional constraints. Where applicable, cross-validation was performed through triangulation of multiple independent sources to ensure robustness of key findings. Throughout, the methodology prioritizes transparency in assumptions and clear linkage between evidence and interpretation so that decision-makers can adapt conclusions to their specific operational and regulatory contexts.

Conclusive synthesis underscoring the imperative for integrated strategies that marry innovation, operational resilience, and customer-centric commercial models in hepatitis diagnostics

In conclusion, hepatitis diagnostics stand at an inflection point where technology sophistication, delivery model evolution, and policy shifts converge to create both opportunity and complexity. Advances across chromatography, immunoassay, and molecular diagnostics are expanding the toolkit available to clinicians and public health practitioners, while shifting care pathways demand solutions that are adaptable across centralized laboratories, clinics, and home care environments. Tariff dynamics and regional heterogeneity add layers of strategic complexity that require deliberate supply chain and commercial planning.

For leaders in this domain, success will come from marrying technical excellence with resilient operations and customer-centric service models. Those who invest in platform flexibility, regional manufacturing strategies, and deep partnerships with end users will be best positioned to translate diagnostic innovation into measurable improvements in detection, linkage to care, and patient outcomes. The evidence underscores the need for coherent strategies that bridge R&D, regulatory, and commercial disciplines to realize the full potential of hepatitis testing advancements.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of point-of-care NAT testing devices with cloud-based patient data management platforms for hepatitis diagnosis
  • 5.2. Adoption of multiplexed rapid diagnostic test panels enabling simultaneous detection of hepatitis B, C and E antigens in resource-limited settings
  • 5.3. Development of digital immunoassay platforms leveraging smartphone readouts for quantitative monitoring of hepatitis B surface antigen levels
  • 5.4. Growing use of CRISPR-based molecular diagnostics for ultra-sensitive detection of hepatitis C viral RNA at the point of care
  • 5.5. Rising investments in microfluidic lab-on-a-chip devices for portable, low-cost hepatitis serological testing in rural clinics
  • 5.6. Expansion of hepatitis screening initiatives through at-home self-collection kits with telehealth integration for underserved populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hepatitis Test Solution/Diagnosis Market, by Technology

  • 8.1. Chromatography
    • 8.1.1. Fia
    • 8.1.2. Hplc
  • 8.2. Immunoassay
    • 8.2.1. Chemiluminescent Immunoassays
    • 8.2.2. Elisa
    • 8.2.3. Rapid Immunoassays
  • 8.3. Molecular Diagnostics
    • 8.3.1. Isothermal Amplification
    • 8.3.2. Pcr
    • 8.3.3. Real-Time Pcr

9. Hepatitis Test Solution/Diagnosis Market, by Product Type

  • 9.1. Instruments
    • 9.1.1. Bench-Top Instruments
    • 9.1.2. High-Throughput Instruments
  • 9.2. Kits & Reagents
    • 9.2.1. Chromatography Kits
    • 9.2.2. Immunoassay Kits
    • 9.2.3. Molecular Assay Kits
  • 9.3. Software & Services

10. Hepatitis Test Solution/Diagnosis Market, by End User

  • 10.1. Blood Banks
  • 10.2. Clinics
  • 10.3. Diagnostic Laboratories
    • 10.3.1. Hospital-Based Laboratories
    • 10.3.2. Independent Laboratories
  • 10.4. Home Care Settings
  • 10.5. Hospitals
    • 10.5.1. General Hospitals
    • 10.5.2. Specialized Hospitals

11. Hepatitis Test Solution/Diagnosis Market, by Test Type

  • 11.1. Confirmatory Tests
    • 11.1.1. Elisa Confirmatory
    • 11.1.2. Pcr Confirmatory
  • 11.2. Screening Tests

12. Hepatitis Test Solution/Diagnosis Market, by Application

  • 12.1. Clinical Diagnostics
  • 12.2. Research

13. Hepatitis Test Solution/Diagnosis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hepatitis Test Solution/Diagnosis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hepatitis Test Solution/Diagnosis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. AbbVie Inc.
    • 16.3.3. Avantor Inc.
    • 16.3.4. Beckman Coulter, Inc.
    • 16.3.5. Bio-Rad Laboratories Inc.
    • 16.3.6. bioMerieux SA
    • 16.3.7. Cepheid
    • 16.3.8. Creative Diagnostics
    • 16.3.9. DiaSorin S.p.A.
    • 16.3.10. Epitope Diagnostics, Inc.
    • 16.3.11. Everlywell, Inc.
    • 16.3.12. F. Hoffmann-La Roche AG
    • 16.3.13. FUJIREBIO Inc.
    • 16.3.14. GenMark Diagnostics, Inc.
    • 16.3.15. Grifols S.A.
    • 16.3.16. Hologic, Inc.
    • 16.3.17. Laboratory Corporation of America Holdings
    • 16.3.18. MedMira Inc.
    • 16.3.19. Merck & Co., Inc
    • 16.3.20. Meridian Bioscience, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY FIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY FIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY FIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY FIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY FIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY FIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HPLC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HPLC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HPLC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HPLC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HPLC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HPLC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RAPID IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HIGH-THROUGHPUT INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HIGH-THROUGHPUT INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HIGH-THROUGHPUT INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HIGH-THROUGHPUT INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HIGH-THROUGHPUT INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HIGH-THROUGHPUT INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR ASSAY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR ASSAY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR ASSAY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR ASSAY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR ASSAY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SPECIALIZED HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SPECIALIZED HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SPECIALIZED HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SPECIALIZED HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SPECIALIZED HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SPECIALIZED HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ELISA CONFIRMATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ELISA CONFIRMATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ELISA CONFIRMATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ELISA CONFIRMATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ELISA CONFIRMATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY ELISA CONFIRMATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PCR CONFIRMATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PCR CONFIRMATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PCR CONFIRMATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PCR CONFIRMATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PCR CONFIRMATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PCR CONFIRMATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SCREENING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SCREENING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SCREENING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SCREENING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SCREENING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SCREENING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA HEPATITIS TEST SOLUTION/DIAGNOSIS MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH